Ketamine for MS Fatigue

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue. The investigator proposes a prospective, crossover, randomized, placebo-controlled study to assess the efficacy and safety of low, single dose Ketamine, to assess its efficacy and safety in patients with MS-related fatigue.

Key facts

Study ID
NCT06064162
Run by
Alta Bates Summit Medical Center
People needed
21
Starts
2023-12-05
Expected to finish
2025-05-05
Last updated by the study team
2025-06-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.